How does the 30-day cost of Relvar for the treatment of asthma compare to other ICS/LABA combination inhalers?
Please click on the thumbnail to the left to view and download a pdf copy of a cost comparison chart of ICS/LABAs available for the treatment of asthma. Relvar Ellipta low-mid dose (92/22mcg) and high dose (184/22mcg) are highlighted in orange.
The cost comparison chart is updated regularly to reflect the change in list price of ICS/LABAs inhalers.
If you would like to estimate the potential financial impact of adopting Relvar Ellipta for the treatment of asthma in your health economy please contact a Health Outcomes Consultant (HOC). The HOC will model and localise the estimate using prescribing data for your own health economy.
To arrange a meeting with a HOC use the following link:
Please state your preference to either meet in person, telephone or on-line.